CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that the first patient has been dosed in the phase 2 study of tazemetostat in adult patients with genetically defined tumors. The phase 1 dose escalation study in pediatric patients …